|Primary Care Antimicrobial Guidelines |
|Chapter 5.6 has indication specific guidance for antimicrobial therapy
|National Reporting and Learning System (NRLS) |
|NHS England have launched a simplified form that enables GPs to report patient safety incidents (including prescribing errors) directly into the National Reporting and Learning System (NRLS) from their webpage.
|MHRA Yellow Card Scheme |
|The Yellow Card Scheme now supports the reporting of all suspected problems or incidents to all healthcare products, not just suspected side effects to medicines.
NetFormulary UPDATE news
NEW drugs added to the formulary:-
Chapter 12 - Azelastine and fluticasone (Dymista) [Sept 16]
Chapter 6 - Dulaglutide (Trulicity® ) [Oct 16]
Chapter 2 - Midodrine - (Bramox) [Nov 16]
Chapter 13 - Adapalene 0.1%/benzoyl peroxide 2.5% Gel (Epiduo 0.1%/2.5% Gel) [Nov 16]
Chapter 13 - Calcipotriol monohydrate 50mcg/g and betamethasone diproprionate 0.5mg/g cutaneous foam (Enstilar®) [Nov 16]
Chapter 4 - Levetiracetam granules in sachets (Desitrend®) [Dec 16]
Chapter 4 - Sodium valproate prolonged release granules in capsules and sachets. (Episenta®) [Dec 16]
Chapter 6 - Alendronate 70mg effervescent tablets (Binosto®) [Dec 16]
Chapter 3 - Hypertonic sodium chloride (Resp-Ease) [Dec 16]
Chapter 13 - Propantheline bromide [Dec 16]
NetFormulary UPDATE news
Chapter 15 Anaesthesia
NetFormulary UPDATE news
Chapter 13 - Skin
Chapter 14 - Immunological products and vaccines
NetFormulary UPDATE news
The following sections have been updated with the Area Prescribing Committee (APC) recommendations:-
Chapter 6 - Contraceptives section
Chapter 8 - Malignant disease and immunosuppression
Chapter 9 - Nutrition and blood
Chapter 11 - Eye
Chapter 12 - Ear, nose, and oropharynx
Chapter 13 - Skin (thus far.....)
NetFormulary UPDATE news:- Please note that all Effective Shared Care Agreements (ESCAs) and Rationale for Initiation, Continuation and Discontinuation (RICaDs) approved to date have been uploaded onto the formulary and linked to individual drug monographs.
UPDATE NEWS - Chapter 4, 6 (some sections still under review), 7 (some sections still under review) & 10 have now been updated.
>>> more news
A formulary is a locally maintained document which lists the medicines that are deemed suitable for prescribing within the clinical commissioning group. Medicines that are included on the local formulary are assessed by a committee of clinicians and medicines experts for their suitability for local use.
The committee will generally assess medicines in terms of safety, clinical effectiveness, cost effectiveness and patient preferences. Most medicines accepted for use will be prescribable by primary and secondary care but some will have local restrictions on their use. Some will be prescribable in limited circumstances and some will only be prescribable in hospital settings. Some medicines won't be included on the formulary at all. All prescribers are expected to take into account whether the medicine they intend to prescribe is on the formulary. Use of the formulary is not mandatory but prescribers are strongly encouraged to consider formulary medicines first.
In Birmingham CrossCity Clinical Commissioning Group, there are multiple local formularies - the main ones being the Heart of England Foundation Trust, University Hospitals Birmingham Foundation Trust and Sandwell and West Birmingham Hospitals NHS Trust. Whilst the formularies are similar, there remain some historical differences that the CCG is committed to resolving.
Please be aware this formulary website is live information that is updated regularly and that it is currently in the first few months of deployment within our CCG. We welcome any feedback you may have regarding layout, accuracy and any additional information that would be of benefit when selecting medication. You can email us feedback using the 'Feedback' option located in the top menu of this page and we will review your comments to continually improve the service.
Traffic Light Status Information
||Green Formulary Status|
These preparations are prescribable within primary and secondary care and are considered first line
||Amber Formulary Status|
These medicines are considered suitable for prescribing in primary care following specialist initiation or recommendation to initiate therapy. Some of these medicines require on-going communication between the secondary specialist and primary care prescriber through the use of an Effective Shared Care Agreement (ESCA).
||Yellow Formulary Status|
These preparations are prescribable within primary and secondary care and are considered as either second line or they are restricted in some other way e.g. the use may be unlicensed/off label. Where a restriction applies, it is stated in the additional information section.
||Amber Restricted Formulary Status|
Drugs marked as restricted with an amber status are available for use in restricted circumstances; they may be restricted to certain specialties or for treating certain diseases, or for use when a first-line treatment has not worked. Where clinically appropriate, prescribing of restricted drugs may be passed to primary care on the advice of a Specialist.
||Double Amber Formulary Status|
These preparations are prescribable within primary and secondary care and however their use is further restricted. Restrictions are stated in the additional information section. In addition to the restrictions, medicines in this column may require an ESCA (Effective Shared Care Agreement) or a RICaD (Rationale for Initiation, Continuation and Discontinuation) to be completed before prescribing can be undertaken in Primary care. ESCAs and RICaDs are developed via collaboration between the Formulary Working Group and the relevant specialists.
||Double Yellow Formulary Status|
These preparations are prescribable within primary and secondary care and however their use is further restricted. ? Restrictions are stated in the additional information section. In addition to the restrictions, medicines in this column may require an ESCA (Effective Shared Care Agreement) or a RICaD (Rationale for Initiation, Continuation and Discontinuation) to be completed before prescribing can be undertaken in Primary care. ESCAs and RICaDs are developed via collaboration between the Formulary Working Group and the relevant specialists.
||NICE Approved Formulary Status|
Drugs which are approved by NICE in a technology appraisal are available for use in the Trust. All other drugs are available on Consultant request provided the request is authorized by a medical director or an officer of the Drug and Therapeutics committee.
||Red Formulary Status|
These drugs are for specialist use only. They should not be prescribed in primary care unless by a GP with special interest.
These medicines should be initiated by specialists only, and prescribing where possible is retained within secondary care. Such medications require specialist knowledge, monitoring, dose adjustments or further evaluation while in use. Intravenous medicines or unlicensed indications for specialist medicines would routinely fall into this category.
||Variable Formulary Status|
The Blue Status only denotes a variable formulary status, thus prescribing should follow the individual formulary status as listed in the section on the right hand side.
||Black Formulary Status|
Shows those items with a Non-Formulary status following a review by the Area Prescribing Committee.